Healthcare / BiotechnologyNasdaqCM
$2.28
+0.03 (+1.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-9.8M · quality 37.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$19M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-66.5%
↓Gross Margin
-334.3%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-493.8%
FCF / Net income
1.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.0M · net income $-9.6M · FCF $-9.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $2.0M | $2.0M | $11.2M | $-2.9M | $500000.00 | $16.1M | $0.00 | $164990.00 | $428031.00 | $0.00 | $0.00 | — | — | $0.00 | $7.7M | — |
| Net Income | $-9.6M | $-9.6M | $8352.00 | $-16.4M | $-10.8M | $-634399.00 | $-21.0M | $-13.0M | $-11.7M | $-21.0M | $-19.0M | $-18.2M | $-20.4M | $-10.6M | $3.9M | $-5162.00 |
| EBITDA | $-10.3M | $-10.3M | $-1.1M | $-17.9M | $-10.7M | $3.1M | $-18.0M | $-12.9M | $-11.3M | $-21.2M | $-19.2M | $-18.4M | $-20.5M | $-10.7M | $3.9M | — |
| EPS | -1.77 | -1.77 | — | -3.14 | -2.21 | -0.17 | -6.46 | -8.50 | -9.35 | -17.85 | -17.68 | -18.87 | -27.20 | -24.48 | 14.45 | — |
| Gross Margin | -334.3% | -334.3% | 34.3% | 456.9% | -1611.4% | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -524.7% | -524.7% | -10.3% | 629.0% | -2423.9% | 19.5% | — | -7818.8% | -2646.0% | — | — | — | — | — | 50.3% | — |
| Net Margin | -487.1% | -487.1% | 0.1% | 573.6% | -2151.7% | -3.9% | — | -7883.7% | -2724.1% | — | — | — | — | — | 50.4% | — |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | — | — | — | — | — | 0.04 | 0.15 | 0.61 | 0.73 | 0.00 | — | — | — | — | — | — |
| Current Ratio | 9.99 | 9.99 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-9.8M | $-9.8M | $-1.3M | $-11.9M | $-12.1M | $-4.4M | — | — | $-12.1M | $-16.7M | $-18.3M | $-15.4M | — | $-8.6M | $-3.2M | — |
| Returns | ||||||||||||||||
| ROE | -66.5% | -66.5% | 0.0% | -80.3% | -30.2% | -1.4% | -136.7% | -206.9% | -123.6% | -110.6% | -72.9% | -43.4% | -77.3% | -23.6% | 73.1% | -0.4% |
| Valuation | ||||||||||||||||
| P/B | 0.90 | 0.90 | 1.31 | 0.75 | 1.20 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | -82.3% | -82.3% | 492.8% | -670.2% | — | — | -100.0% | -61.5% | — | — | — | — | — | -100.0% | — | — |
| EPS Growth | — | — | — | -42.1% | — | 97.4% | 24.0% | 9.1% | 47.6% | -1.0% | 6.3% | 30.6% | -11.1% | -269.4% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.5%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → -1.77
Residual
-32.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.